Peer-reviewed veterinary case report
c-met protein levels linked to prognosis in dog mammary tumors
By Chen, Yi-Chen et al.·Published in Veterinary and comparative oncology·2018·Graduate Institute of Veterinary Pathobiology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Expression and prognostic value of c-met in canine mammary tumours.
- Species:
- dog
Plain-English summary
A study looked at the c-met protein in mammary tumors from female dogs, which are the most common type of tumor in this species. Researchers found that higher levels of c-met in malignant tumors were linked to better survival rates, with 80% of dogs showing higher c-met expression surviving for at least two years compared to 57% of those with lower levels. Dogs with larger tumors or those that had spread to lymph nodes had shorter survival times. This suggests that measuring c-met levels could help predict outcomes for dogs with breast cancer.
People also search for: dog mammary tumor prognosis · c-met expression in dog cancer · female dog breast cancer survival rate
Abstract
C-met is a receptor normally expressed on epithelial cells and dysregulated in human breast cancers. Mammary tumours are the most common tumour in female dogs. The aims of this study were to detect the expression of c-met in canine mammary tumours (CMTs) and evaluate the correlations between c-met expression and clinicopathological features. A total of 240 specimens of canine mammary tissues composed of 30 normal glands, 30 hyperplastic ones, 90 benign tumours and 90 carcinomas obtained from 127 bitches were examined by immunohistochemical staining. Positive c-met immunoreactivity was demonstrated in the cytoplasm of mammary epithelial cells at variable levels, and in malignant CMTs, higher c-met expression was found in carcinomas whose grade, stage and mitotic index were low, and metastasis was absent. The median survival time was shorter in dogs with malignant CMTs with a maximum diameter ≥5 cm, regional lymph node or distant metastasis, and a high histologic grade. However, the 2-year survival rate was higher in dogs with malignant CMTs of higher c-met expression than those of low c-met expression (80.1% vs 57%). C-met expression could be used as a valuable positive prognostic factor for the clinical outcomes of dogs with malignant CMTs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30129270/